UNSPSC 51371510: Tilidine phosphate

This classification denotes an opioid analgesic C17H23NO2.H3O4P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PJ7Z0WL915, chemically known as 3-cyclohexene-1-carboxylic acid, 2-(dimethylamino)-1-phenyl-, ethyl ester, trans-(+/-)-, phosphate (1:1), but more generally known as tilidine phosphate, which bears US NIH Compound Identifier 71587539. European Medicines Agency schedules Tilidine phosphate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20755.

Most nations, for tariff and trade purposes, schedule tilidine phosphate under HS 29224400 and SITC 51465. As of Q4 2014, TILIDINE PHOSPHATE remains US FDA's Preferred Term for this commodity. SMILES: CCOC(=O)[C@]1(CCC=C[C@@H]1N(C)C)C2CCCCC2.OP(=O)(O)O.

UNSPSC 51371510 Tilidine phosphate is a Commodity code that nominally describes a specific pharmaceutical ingredient, but recent state and local opportunities tagged under this code do not align with tilidine phosphate procurement. Instead, the code captures a broader mix of pharmaceutical and health-related product acquisitions, including naloxone systems, generic multi-source pharmaceuticals, and over-the-counter products distributed through state and local health agencies. The recent solicitations reflect purchases by county health departments, state health commissions, and cooperative purchasing alliances seeking to acquire finished pharmaceutical products and medical supplies for community health initiatives, emergency response programs, and employee health plans rather than tilidine phosphate specifically. Issuing bodies include county governments (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing organizations (Minnesota Multistate Cooperative Purchasing Alliance, serving state and local government members across multiple jurisdictions including Oregon).

Geographic activity concentrates in Florida, Texas, and Minnesota, with multistate cooperative purchasing extending to Oregon and other participating jurisdictions. Representative recent opportunities include Seminole County's IFB60459723LAS, an IFB posted June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023; the Texas Health and Human Services Commission's RFI HHS0017013 posted April 3, 2026, exploring vendor capabilities for direct-to-manufacturer prescription programs without pharmacy benefit managers; and MMCAP's S1070000015802, an RFP posted January 20, 2026, with a response deadline of March 26, 2026, establishing multi-award contracts for generic pharmaceuticals and OTC products through authorized wholesalers. The mismatch between the code's nominal scope (tilidine phosphate) and actual procurement activity suggests tagging inconsistency rather than active demand for tilidine phosphate itself in state and local procurement.